Clustering data with hclust algorithm for (Study ST002127)

(Analysis AN003480)
MetaboliteStructureF1F2F3F4F5F6F7F8
[13C]Alpha_KetoglutarateME516749NA5.530.100.08NA0.060.140.09
[13C]MalateME516752NA0.681.100.94NA0.891.291.09
[13C]CitrateME516750NA0.601.170.98NA0.711.381.17
[13C]FumatateME516751NA0.641.300.99NA0.561.411.11
[13C]SuccinateME516753NA0.681.230.98NA0.621.381.10
[13C, 15N]Glycine, 2TBDMSME5167370.021.730.821.290.021.800.951.38
[13C, 15N]Alanine, 2TBDMSME5167340.232.260.621.030.222.220.510.91
[13C, 15N]Proline, 2TBDMSME5167440.232.300.611.120.222.170.400.95
[13C, 15N]Aspartic acid, 3TBDMSME5167350.191.880.801.210.191.880.711.14
[13C, 15N]Isoleucine, 2TBDMSME5167390.171.740.751.240.201.970.651.27
[13C, 15N]Phenylalanine, 2TBDMSME5167430.212.060.931.080.181.850.710.98
[13C, 15N]Threonine, 3TBDMSME5167460.212.100.841.230.181.840.660.93
[13C, 15N]Serine, 3TBDMSME5167450.201.950.571.300.212.130.491.15
[13C, 15N]Glutamic acid, 3TBDMSME5167360.202.030.751.300.202.000.570.96
[13C, 15N]Lysine, 3TBDMSME5167410.191.940.801.100.202.040.631.10
[13C, 15N]Methionine, 2TBDMSME5167420.202.010.681.140.202.040.581.14
[13C, 15N]Valine, 2TBDMSME5167480.202.010.751.190.202.030.571.05
[13C, 15N]Tyrosine, 3TBDMSME5167470.222.170.711.110.202.050.560.98
[13C, 15N]Histidine, 3TBDMSME5167380.232.250.641.240.202.000.470.98
[13C, 15N]Leucine, 2TBDMSME5167400.212.130.641.330.202.000.481.01

Factors:

F1Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:Ctrl, [13C, 15N] AAs were incorporated for 1 h | Batch:1e | Note:[13C, 15N]AAs were used for AA uptake (FigS6.J)
F2Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:Ctrl, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1e | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).
F3Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:Ctrl, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1e | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).
F4Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:Ctrl, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1e | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).
F5Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 1 week, [13C, 15N] AAs were incorporated for 1 h | Batch:1e | Note:[13C, 15N]AAs were used for AA uptake (FigS6.J)
F6Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 1 week, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1e | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).
F7Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 1 week, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1e | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).
F8Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 1 week, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1e | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).
Data matrix
  logo